Asset Details
Do you wish to reserve the book?
HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer
Do you wish to request the book?
HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer
2023
Overview
There is increasing evidence that hexokinase is involved in cell proliferation and migration. However, the function of the hexokinase domain containing protein‐1 (HKDC1) in gastric cancer (GC) remains unclear. Immunohistochemistry analysis and big data mining were used to evaluate the correlation between HKDC1 expression and clinical features in GC. In addition, the biological function and molecular mechanism of HKDC1 in GC were studied by in vitro and in vivo assays. Our study indicated that HKDC1 expression was upregulated in GC tissues compared with adjacent nontumor tissues. High expression of HKDC1 was associated with worse prognosis. Functional experiments demonstrated that HKDC1 upregulation promoted glycolysis, cell proliferation, and tumorigenesis. In addition, HKDC1 could enhance GC invasion and metastasis by inducing epithelial–mesenchymal transition (EMT). Abrogation of HKDC1 could effectively attenuate its oncogenic and metastatic function. Moreover, HKDC1 promoted GC proliferation and migration in vivo. HKDC1 overexpression conferred chemoresistance to cisplatin, oxaliplatin, and 5‐fluorouracil (5‐Fu) onto GC cells. Furthermore, nuclear factor kappa‐B (NF‐κB) inhibitor PS‐341 could attenuate tumorigenesis, metastasis, and drug resistance ability induced by HKDC1 overexpression in GC cells. Our results highlight a critical role of HKDC1 in promoting glycolysis, tumorigenesis, and EMT of GC cells via activating the NF‐κB pathway. In addition, HKDC1‐mediated drug resistance was associated with DNA damage repair, which further activated NF‐κB signaling. HKDC1 upregulation may be used as a potential indicator for choosing an effective chemotherapy regimen for GC patients undergoing chemotherapy. HKDC1 upregulation predicts resistance to cisplatin, oxaliplatin and 5‐FU in patients with GC. HKDC1 upregulation may be used as a potential indicator for choosing an effective chemotherapy regimen for GC patients undergoing chemotherapy.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Antigens
/ Disease
/ Drug Resistance, Neoplasm - genetics
/ Epithelial-Mesenchymal Transition - genetics
/ Gene Expression Regulation, Neoplastic
/ Genomes
/ Glucose
/ HKDC1
/ Humans
/ Kinases
/ Original
/ Proteins
/ Stomach Neoplasms - drug therapy
/ Stomach Neoplasms - genetics
/ Stomach Neoplasms - metabolism
/ Tumors
